Further Characterization of Quinpirole-Elicited Yawning as a Model of Dopamine D₃ Receptor Activation in Male and Female Monkeys

Susan E. Martelle, Susan H. Nader, Paul W. Czoty, William S. John, Angela N. Duke, Pradeep K. Garg, Sudha Garg, Amy H. Newman, and Michael A. Nader

Departments of Physiology and Pharmacology (S.E.M., S.H.N., P.W.C., W.S.J., A.N.D., M.A.N.) and Radiology (P.K.G., S.G., M.A.N.), Wake Forest School of Medicine, Winston-Salem, North Carolina; and the Intramural Research Program (A.H.N.), National Institute on Drug Abuse, Baltimore, Maryland

Received March 20, 2014; accepted May 28, 2014

ABSTRACT

The dopamine (DA) D₃ receptor (D3R) has been associated with impulsivity, pathologic gambling, and drug addiction, making it a potential target for pharmacotherapy development. Positron emission tomography studies using the D3R-preferring radioligand [¹¹C]PHNO ([¹¹C](+)-propyl-hexahydro-naphtho-oxazin) have shown higher binding potentials in drug abusers compared with control subjects. Preclinical studies have examined D3R receptor activation using the DA agonist quinpirole and the unconditioned behavior of yawning. However, the relationship between quinpirole-elicited yawning and D3R receptor availability has not been determined. In Experiment 1, eight drug-naïve male rhesus monkeys were scanned with [¹¹C]PHNO, and the ability of quinpirole (0.01–0.3 mg/kg i.m.) to elicit yawning was examined. Significant positive (globus pallidus) and negative (caudate nucleus, putamen, ventral pallidum, and hippocampus) relationships between D3R receptor availability and quinpirole-induced

yawns were noted. Experiment 2 replicated earlier findings that a history of cocaine self-administration ($n = 11$) did not affect quinpirole-induced yawning and extended this to examine monkeys ($n = 3$) with a history of methamphetamine (MA) self-administration and found that monkeys with experience self-administering MA showed greater potency and significantly higher quinpirole-elicited yawning compared with controls. Finally, quinpirole-elicited yawning was studied in drug-naïve female monkeys ($n = 6$) and compared with drug-naïve male monkeys ($n = 8$). Sex differences were noted, with quinpirole being more potent and eliciting significantly more yawns in males compared with females. Taken together these findings support the use of quinpirole-elicited yawning as a behavioral tool for examining D3R activation in monkeys and that both drug history and sex may influence individual sensitivity to the behavioral effects of D3R compounds.

Introduction

Psychostimulant drug use is a global problem. In 2011, the United Nations Office on Drugs and Crime estimated 14 to 21 million people worldwide used cocaine at least once in 2009, with 20% of users in the United States meeting the criteria of drug dependence (Degenhardt and Hall, 2012). Despite the array of negative health and societal consequences, a successful pharmacotherapy for psychostimulant addiction has remained elusive (Newman et al., 2005, 2012). There is evidence that dopamine (DA) D₃ receptors (D3R), a subtype of the D2-like

family of DA receptors, mediate many of the effects of psychostimulants associated with high abuse potential (Heidbreder and Newman, 2010; Heidbreder, 2013), including the role of conditioned stimuli (Neisewander et al., 2004; Achat-Mendes et al., 2009; Orio et al., 2010; Yan et al., 2013), discriminative stimulus effects (Martelle et al., 2007; Achat-Mendes et al., 2009; Collins and Woods, 2009), and cue conditioning (Le Foll et al., 2002). In addition, D3R partial agonists and antagonists have been shown to reduce self-administration of methamphetamine (MA) in a rodent model of compulsive drug intake (Orio et al., 2010). Postmortem studies indicate higher D3R densities in cocaine overdose victims compared with age-matched controls (Staley and Mash, 1996; Segal et al., 1997), supporting a role for this receptor subtype in drug addiction. Finally, recent brain imaging studies in humans using the positron emission tomography (PET) D3R-preferring ligand [¹¹C]PHNO ([¹¹C](+)-propyl-hexahydro-naphtho-oxazin) revealed that D3R availability was higher in MA polydrug users (Boileau et al., 2012) and cocaine-dependent

The research described in this manuscript was supported by grants from the National Institutes of Health National Institute on Drug Abuse [Grants DA012460 and DA021658]; the National Institutes of Health National Institute on Alcohol Abuse and Alcoholism [Grant AA021099]; and the Intramural Research Program of the National Institutes of Health [National Institute on Drug Abuse].
dx.doi.org/10.1124/jpet.114.214833.

ABBREVIATIONS: ANOVA, analysis of variance; BP_{ND}, binding potential; Cd, caudate nucleus; [¹¹C]PHNO, [¹¹C](+)-propyl-hexahydro-naphtho-oxazin; DA, dopamine; DAT, dopamine transporter; D2R, dopamine D₂ receptor; D3R, dopamine D₃ receptor; GP, globus pallidus; GSK598809, 5-(5-((3-((1S,5R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole; HIP, hippocampus; MA, methamphetamine; MRI, magnetic resonance imaging; PET, positron emission tomography; Pt, putamen; ROI, regions of interest; VP, ventral pallidum.

individuals (Payer et al., 2014) compared with age-matched controls, an outcome opposite to the decreases in D2-like receptor availability after chronic stimulant exposure (e.g., Volkow et al., 1990, 2001; Nader et al., 2006).

A behavioral assay that has been frequently used to characterize D3R agonists is the unconditioned behavior of drug-elicited yawning using the D₃/D₂ receptor agonist quinpirole in rodents (e.g., Collins et al., 2005, 2007; Baladi and France, 2009) and nonhuman primates (Martelle et al., 2007; Hamilton et al., 2010; Blaylock et al., 2011). The quinpirole-induced yawning dose-response curve is an inverted U-shaped function of dose. Collins et al. (2005, 2007) concluded that the ascending limb of the quinpirole dose-response curve is mediated by D3R, whereas the descending limb is primarily D₂ receptor (D2R)-mediated and coincides with an onset of hypothermia. Despite the differences noted in D2-like and D3R availability after cocaine exposure, quinpirole-elicited yawning was not different in cocaine-naïve versus cocaine-experienced monkeys (Blaylock et al., 2011). However, although D3R partial agonists do not elicit yawning when administered to cocaine-naïve monkeys (Martelle et al., 2007), they do elicit yawning in monkeys with an extensive cocaine history (Blaylock et al., 2011). This finding suggests that drug-elicited yawning may be an effective baseline on which to assess functional consequences of chronic cocaine exposure.

In the present study, we used quinpirole-elicited yawning to examine the relationship between behavioral sensitivity and measures of D3R receptor availability using PET imaging with [¹¹C]PHNO in drug-naïve male rhesus monkeys. Second, we extended previous findings that a cocaine history does not influence sensitivity to quinpirole-elicited yawning (Blaylock et al., 2011; Collins et al., 2011) to monkeys with an extensive MA self-administration history. Finally, recent data investigating D2-like receptor availability in cocaine abuse (Nader et al., 2012) suggested possible sex differences in the relationship between DA receptor function and cocaine abuse. Thus, we examined the effects of quinpirole-elicited yawning in a group of drug-naïve female rhesus monkeys and compared them to drug-naïve male rhesus monkeys.

Materials and Methods

Subjects

Adult rhesus monkeys (*Macaca mulatta*; 22 male, 7 female) served as subjects. At the start of the study, 15 monkeys were drug naïve (8 males and 7 females), three male monkeys had a lifetime intake of methamphetamine ranging from 143 to 200 mg/kg and 11 male monkeys had varying cocaine histories (minimum of 225 mg/kg). Drug-experienced monkeys were previously implanted with a chronic indwelling catheter and associated vascular access port (Access Technologies, Skokie, IL) as described elsewhere (Czoty et al., 2006) and, excluding days of quinpirole-elicited yawning, underwent experimental sessions involving drug self-administration daily (Monday–Friday). All monkeys were fitted with aluminum collars and trained to sit calmly in a primate restraint chair (Primate Products, Redwood City, CA). Monkeys were individually housed in stainless-steel cages with visual and auditory contact with each other, ad libitum access to water in their home cage, and fed sufficient standard laboratory chow (Purina LabDiet 5045; St. Louis, MO) to maintain healthy body weights (determined by veterinary staff and somewhat less than free-feeding weights). Environmental enrichment was provided as outlined in the Animal Care and Use Committee of Wake Forest University Non-Human Primate Environmental Enrichment Plan. Experimental procedures as well as animal housing and handling were

performed in accordance with the 2011 *National Research Council Guidelines for the Care and Use of Laboratory Animals* and were approved by the Animal Care and Use Committee of Wake Forest University.

Experiment 1: Relationship between D3R Availability and Quinpirole-Elicited Yawning

Imaging Procedure. A magnetic resonance imaging (MRI) scan was acquired in seven of eight experimentally naïve male monkeys; monkey #1711 had been previously implanted with a non-MR compatible telemetry device. Monkeys were anesthetized with ketamine (10–15 mg/kg i.m.) approximately 20 minutes prior to scanning, transported to the MRI facility, and T1-weighted images of the entire brain were acquired with a 3.0-T Siemens SKYRA scanner. PET data were coregistered to individual MRIs using PMOD Biomedical Image Quantification Software (version 3.1; PMOD Technologies, Zurich, Switzerland). Spherical regions of interest (ROI) were drawn on individual MR images for the caudate nucleus (Cd; 2.5 mm radii), putamen (Pt; 2.5 mm radii), globus pallidus (GP; 2.5 mm radii), ventral striatum (2.0 mm radii), ventral pallidum (VP; 2.0 mm radii), thalamus (3.0 mm radii), substantia nigra (2.0 mm radii), hippocampus (HIP; 2.4 mm radii), and cerebellum (4.0 mm radii). The GP, VP, thalamus, and substantia nigra were chosen because they are rich in D3R (Tziortzi et al., 2011), the Cd, Pt, and ventral striatum were chosen because of their involvement in addiction (Koob and Volkow, 2010), and the HIP because of its role in yawning (Argiolas and Melis, 1998). For monkey #1711, the PET data were coregistered to the MRI obtained from monkey #1710 based on the similar weight and age of the two subjects.

PET studies were performed on a GE 64 slice PET/CT Discovery VCT scanner (GE Medical Systems, Milwaukee, WI) with an approximate 5- to 6-mm resolution, using the D3R radiotracer [¹¹C]PHNO, synthesized as described in Wilson et al. (2005). On the day of the PET study, monkeys ($n = 8$) were initially anesthetized with 10–15 mg/kg (i.m.) ketamine HCl and transported to the PET center where they were maintained on inhaled 1.5% isoflurane anesthesia for the duration of the 90-minute PET scan. Arterial and venous catheters were placed by percutaneous stick for blood pressure and tracer injection, respectively. Because of an irregular respiratory rate and hypotension after injection of the radiotracer, two monkeys were put on a ventilator for the remainder of the scan. This effect after tracer doses of PHNO was previously reported (Gallazot et al., 2012). At the start of the PET scan, 4–6 mCi of [¹¹C]PHNO was injected, followed by a 90-minute three-dimensional emission scan consisting of 36 sequential frames: 10 × 6 seconds (0–1 minute), 5 × 1 minutes (1–6 minutes), 7 × 2 minutes (6–20 minutes), 14 × 5 minutes (20–90 minutes). Initiation of each PET scan coincided with intravenous injection of [¹¹C]PHNO. The three-dimensional data were attenuation corrected and reconstructed transaxially using OSEM VUE point (28 subsets; 2 iterations) with a 3-mm FWHM filter resulting in a 128 × 128 matrix. PET studies were obtained prior to examining cumulative quinpirole-elicited yawning dose-response curves.

Quinpirole-Elicited Yawning. On the day of testing, monkeys were not fed before the experiment. Prior to the start of the session, monkeys were taken from the home cage, placed in a primate chair, and transferred to a quiet procedure room that contained a camera for video recording. They were allowed to habituate to the room for 5 minutes. The session was divided into five 30-minute components in which saline was administered before the first component followed by ascending doses of quinpirole (cumulative doses of 0.01, 0.03, 0.1, 0.3 mg/kg) injected intramuscularly in the upper quadriceps. Beginning immediately after each injection, the total number of yawns observed during each 30-minute bin was recorded. Yawning was defined as a full extension of the jaws, withdrawal of lips, and exposure of teeth (Code and Tang, 1991). Temperature was taken by rectal thermometer immediately after the monkey habituated to the room and after completion of each 30-minute bin. It was difficult to obtain body temperature measures in some monkeys after the highest dose of quinpirole. Only data from monkeys with temperature obtained from the entire dose response curve

were used for hypothermia analyses ($n = 4$). Videos were scored by two observers blind to the experimental conditions; the interobserver variability was $<5\%$.

Experiment 2: Effects of Sex and Drug History on Quinpirole-Elicited Yawning

Procedure. Separate groups of monkeys were used in this study and compared with the drug-naïve male monkeys used in Experiment 1. First, we replicated an earlier study using 11 male rhesus monkeys with an extensive history of cocaine self-administration and compared quinpirole-elicited yawning with data obtained from the drug-naïve male monkeys from Experiment 1. Next, we extended this characterization to three male monkeys with an extensive history of MA self-administration ($n = 3$) and, finally, to drug-naïve female rhesus monkeys ($n = 7$). For both the cocaine and MA group, 24 hours elapsed between drug self-administration sessions and quinpirole-elicited yawning. Quinpirole-elicited yawning and body temperature (for drug-naïve females) measures were obtained as described in Experiment 1. After completion of the quinpirole dose-effect curve for the MA group, the lowest dose of quinpirole (0.01 mg/kg) elicited the most yawns. Therefore, the MA group underwent an additional acute session consisting of a saline injection followed 30 minutes later with 0.003 mg/kg quinpirole; this dose was not included in statistical analyses comparing groups.

Data Analysis.

Experiment 1. One-way repeated-measures analyses of variance (ANOVAs) and Bonferroni post hoc analyses were used to analyze quinpirole-induced yawning and hypothermia. For analysis of PET data, a binding potential (BP_{ND}) was calculated for each of the eight ROIs (left hemisphere, right hemisphere, and average) by implementing the simplified reference tissue method (Lammertsma and Hume, 1996) in PMOD using the cerebellum as the reference region, resulting in 24 separate measures of BP_{ND} . Because of the longitudinal nature of these data, repeated-measures mixed models were conducted to account for within-monkey correlations. For these analyses, the total number of yawns at each of the five 30-minute bins was the dependent variable and average BP_{ND} as the independent variable, adjusting for dose of quinpirole. The mixed model analysis has been used in other PHNO studies (Gallezot et al., 2014) and was necessary because of the covariance between structures in the same individuals (Littell et al., 1998). These analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC). Because we could obtain body temperatures from only four monkeys after the highest dose of quinpirole, correlative data of quinpirole-induced hypothermia and BP_{ND} could not be obtained.

Experiment 2. The effects of sex and drug (cocaine and MA) history on quinpirole-elicited yawning were analyzed with separate two-way repeated-measures ANOVAs using group (drug versus naïve and male versus female) and quinpirole dose, followed by post hoc Bonferroni t tests (significance level, $P < 0.05$). Female rhesus quinpirole-induced yawning and hypothermia were analyzed using one-way repeated-measures ANOVAs.

Results

Experiment 1: Relationship between D3R Availability and Quinpirole-Elicited Yawning. In experimentally naïve male rhesus monkeys, quinpirole-elicited yawning varied as a function of dose [$F(4,39) = 3.901$, $P = 0.012$] and was characterized as an inverted U-shaped function of dose, with peak yawns after 0.1 mg/kg (Fig. 1). Post hoc Bonferroni analysis showed that quinpirole elicited significantly more yawns at 0.1 mg/kg ($t = 3.59$, $P < 0.01$) and 0.3 mg/kg ($t = 2.89$, $P < 0.05$) than saline. Body temperature significantly decreased with increasing doses of quinpirole [$F(4,19) = 13.33$, $P = 0.0002$] (Fig. 1). Post hoc Bonferroni analysis revealed temperatures taken after 0.03, 0.1, and 0.3 mg/kg quinpirole were significantly different than

Fig. 1. Quinpirole-elicited yawning (●) and hypothermia (Δ) in experimentally naïve male monkeys. Cumulative quinpirole dose-response curves (saline, 0.01–0.3 mg/kg) for yawning are the mean ($\pm$ S.E.M.) of 8 monkeys and hypothermia is the mean ($\pm$ S.E.M.) of 4 monkeys; each point was obtained over a 30-minute period. * $P < 0.05$ versus saline.

temperatures after saline administration ($t = 3.05$, 4.90 , 5.86 , respectively; $P < 0.05$).

Each monkey was also studied with [^{11}C]PHNO (Table 1). There were no significant differences between BP_{ND} in left and right regions for any ROI (data not shown), thus average values for each BP_{ND} were used for analyses. The highest binding potential was in the putamen, followed by the caudate nucleus and the ventral striatum. In those regions, the between-subject variability was between 5 and 8%. Table 2 summarizes the results of the mixed model analysis for the relationship between quinpirole-elicited yawning and [^{11}C]PHNO BP_{ND} . With the mean binding potential for the caudate nucleus as an example, the beta value of -3.95 means that there are approximately four fewer yawns on average for every 1-unit increase in binding potential. There were significant negative relationships between yawns and BP_{ND} in the Cd ($\beta = -3.95$, $P < 0.0001$), Pt ($\beta = -2.02$, $P < 0.0001$), VP ($\beta = -2.13$, $P = 0.0219$), and HIP ($\beta = -4.68$, $P = 0.0289$) and a significant positive relationship in the GP ($\beta = 4.63$, $P = 0.0002$).

Experiment 2: Effects of Sex and Drug History on Quinpirole-Elicited Yawning. There was a significant effect of quinpirole dose on the frequency of yawns [$F(4,68) = 4.82$, $P = 0.002$] but no significant group differences or interactions between drug-naïve and cocaine-experienced monkeys (Fig. 2, ● versus ○). There was a significant effect of quinpirole dose [$F(4,36) = 5.18$, $P = 0.002$] and a significant interaction [$F(4,36) = 4.55$, $P = 0.005$] between drug-naïve and MA-experienced

TABLE 1

Binding potentials for [^{11}C]PHNO in drug-naïve male rhesus monkeys

	Cd	Pt	VST	VP	GP	SN	HIP	Thal	Yawns ^a
1710	3.39	4.19	2.15	1.37	1.12	0.42	0.39	0.20	27
1711	3.93	4.58	3.12	1.99	1.55	1.66	0.28	0.13	20
1712	2.99	3.11	2.35	1.49	1.00	0.35	0.48	0.30	34
1713	2.55	2.67	1.79	1.25	1.19	0.49	0.14	0.50	39
1763	3.47	3.43	2.38	1.32	2.31	-0.04	0.30	0.12	21
1765	2.56	2.54	1.69	1.36	1.15	0.75	0.25	0.03	44
1706	3.56	3.94	2.82	2.18	1.54	0.67	0.41	0.64	47
1681	3.30	3.67	1.60	1.44	1.24	0.43	0.54	0.62	10
AVG	3.22	3.52	2.24	1.55	1.39	0.59	0.35	0.32	30.25
S.E.M.	0.17	0.25	0.19	0.12	0.15	0.17	0.05	0.09	4.89

SN, substantia nigra; Thal, thalamus; VST, ventral striatum.

^aTotal yawns across the entire quinpirole dose-response curve (0.01–0.3 mg/kg).

TABLE 2

Results of mixed models of total yawns adjusting for dose of quinpirole and accounting for within-monkey correlation

	β	<i>P</i> Value
Caudate	-3.95	<0.0001
Putamen	-2.02	<0.0001
Ventral Striatum	-0.02	0.9703
Ventral Pallidum	-2.13	0.0219
Hippocampus	-4.68	0.0289
Thalamus	0.81	0.4812
Substantia Nigra	-1.02	0.0867
Globus Pallidus	4.63	0.0002
Cerebellum	-2.24	0.2155

monkeys (Fig. 2, ● versus ▲). Post hoc Bonferroni comparisons revealed monkeys with a history of MA self-administration yawned significantly more times than drug-naïve monkeys ($t = 3.25$, $P < 0.05$) at 0.01 mg/kg quinpirole.

There were no significant effects of quinpirole dose on yawning in drug-naïve female monkeys (Fig. 3, ●); the increasing trend at 0.3 mg/kg was due to one monkey yawning 36 times, whereas 5 animals did not yawn after this dose. Body temperature (Fig. 3, ▲) decreased as a function of quinpirole dose [$F(4,34) = 42.14$, $P < 0.0001$]. Post hoc Bonferroni analysis revealed temperatures taken after 0.01, 0.03, 0.1, and 0.3 mg/kg quinpirole were significantly different than temperatures obtained after saline ($t = 2.81, 5.89, 9.19$, and 11.3 , respectively, $P < 0.05$). The results of a two-way ANOVA comparing drug-naïve males (from Experiment 1) and females found significant effects of dose [$F(4,52) = 3.28$, $P = 0.0181$] and sex [$F(4,52) = 6.17$, $P = 0.027$] on quinpirole-elicited yawning. For quinpirole-induced hypothermia, there was a significant effect of quinpirole dose [$F(4,40) = 37.57$, $P < 0.0001$] but no significant effect of sex or interaction.

Discussion

The purpose of the present study was 3-fold. The first objective was to ascertain the relationship between D3R binding potentials and the behavioral effects of the D3-preferring agonist quinpirole in monkeys. PET imaging using the D3-preferring radioligand [^{11}C]PHNO revealed a significant correlation between D3R binding potential and quinpirole-induced yawning in several regions of the brain including the caudate nucleus, putamen,

Fig. 2. Differential effects of drug history on quinpirole-elicited yawning in male rhesus monkeys. Each point represents the mean ($\pm$ S.E.M.) of monkeys with a cocaine history ($n = 11$; ○) and methamphetamine history ($n = 3$; triangles) and drug-naïve controls ($n = 8$; ●). * $P < 0.05$ versus drug-naïve controls.

Fig. 3. Quinpirole-elicited yawning and hypothermia in drug-naïve female monkeys. Each point represents the mean ($\pm$ S.E.M.) of 7 monkeys. All other details are as in Fig. 1. * $P < 0.05$ versus saline.

globus pallidus, ventral pallidum, and hippocampus. The second objective was to test whether a history of MA self-administration differentially affected sensitivity to the unconditioned behavioral effects of quinpirole. With a cumulative quinpirole dosing procedure, differences between MA-experienced monkeys and drug-naïve monkeys were noted, with the MA group showing greater sensitivity to quinpirole. We also replicated an earlier study (Blaylock et al., 2011) showing no differences in quinpirole-elicited yawning between drug-naïve and cocaine-experienced monkeys. Lastly, the comparison of drug-naïve male and female monkeys revealed sex differences, with quinpirole showing greater efficacy and greater potency in eliciting yawning in males compared with females. These findings suggest that the unconditioned behavior of quinpirole-elicited yawning reflects D3R function in monkeys and that both sex and drug history are determinants of individual sensitivity.

Receptor autoradiography studies have indicated similar D3R receptor distribution in nonhuman primates compared with humans (Levant, 1998; Morissette et al., 1998; Sun et al., 2012). In the present study, the highest uptake and binding potentials were in the caudate nucleus, putamen, and ventral striatum. Previous studies in humans found a similar pattern of distribution of PHNO binding, with highest binding potentials in the putamen, globus pallidus, and substantia nigra (Searle et al., 2010; Boileau et al., 2012; Gallezot et al., 2014). Tziortzi and colleagues (2011) used the D3R antagonist GSK598809 [5-(5-((3-((1S,5R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole] to better determine the contribution of D3R and D2R to the PHNO signal in various brain regions. These investigators found that 100% of PHNO signal in the substantia nigra and hypothalamus and the majority of the signal in the ventral pallidum and globus pallidus were D3R-mediated. In contrast, only 20% of the signal in the ventral striatum was attributed to D3R, whereas 100% of the signal in the caudate nucleus was a result of D2R binding (Tziortzi et al., 2011). Because the ascending limb of the quinpirole-elicited yawning dose-response curve is thought to be D3R-mediated (Collins et al., 2005, 2007), the results of the mixed model, which showed approximately five greater yawns for every 1-unit increase in binding potential in the globus pallidus, support this conclusion. Furthermore, in the present study, yawning was negatively correlated with binding in the caudate nucleus and putamen,

consistent with predominant D2R-mediated signal associated with [^{11}C]PHNO binding potential and pharmacological studies suggesting that the descending limb of the quinpirole-elicited yawning dose-response curve is D2R-mediated (Collins et al., 2005, 2007).

Recent PET studies of chronic cocaine (Payer et al., 2014) and polydrug MA (Boileau et al., 2012) users reported that both drugs were associated with elevated levels of D3R availability in the substantia nigra. Furthermore, the use of cocaine and MA has previously been shown to be associated with decreased D2-like receptor availability (Volkow et al., 1990, 2001; Nader et al., 2006; Payer et al., 2014). In the present study, quinpirole-elicited yawning was used to assess group differences in D3R activity in monkeys with a cocaine or MA history and drug-naïve male monkeys. In drug-naïve monkeys, the quinpirole dose-response curve was an inverted U-shaped function of dose, as has been reported previously in monkeys (Martelle et al., 2007; Hamilton et al., 2010; Blaylock et al., 2011). Similarly, quinpirole-elicited yawning was not different between drug-naïve and cocaine-exposed monkeys (Blaylock et al., 2011), although there was substantial individual-subject variability in the quinpirole dose-response curves. The reasons for these individual differences are not yet determined but may be due to differences in cocaine intake. Consistent with the present findings, a recent study found substantial individual subject differences in the reinforcing effects of D3R agonists, quinpirole, pramipexole, and ropinirole (Koffarnus et al., 2012), which may be due to differences in cocaine self-administration histories. Additional studies are needed to better understand how different cocaine exposures affect D3R compounds.

In contrast to the lack of differences between drug-naïve and cocaine-exposed monkeys, MA-exposed monkeys were more sensitive to the behavioral effects of quinpirole compared with control monkeys. Changes in sensitivity on the ascending limb of the quinpirole dose-response curve have been hypothesized to be due to upregulation of D3R and/or downregulation of D2R (Collins et al., 2011); PET and receptor autoradiography studies support this mechanism after long-term MA exposure (Kuczenski et al., 2009; Boileau et al., 2012). It also remains possible that changes in DA transporter (DAT) and subsequent changes in extracellular DA may interact with quinpirole's effects at D3R and D2R. Consistent with this hypothesis is that MA exposure has been shown to decrease DAT (Chu et al., 2008; Groman et al., 2013), whereas chronic cocaine exposure has been reported to increase DAT density (Letchworth et al., 2001). Irrespective of the mechanisms, the present findings suggest that despite both stimulants resulting in increases in [^{11}C]PHNO binding (Boileau et al., 2012; Payer et al., 2014), the behavioral effects of D3R compounds may be different in subjects with a MA history compared with a cocaine history.

There is accumulating evidence of sex differences in cocaine abuse (O'Brien and Anthony, 2005), including greater vulnerability in initiating drug use, progressing to dependence faster, and more adverse physical, mental, and social consequences of abuse in women compared with men (Zilberman et al., 2003; Greenfield et al., 2010). Several animal models using female subjects have supported these observations (e.g., Lynch et al., 2002; Mello et al., 2007; Mello, 2010; Nader et al., 2012). As it relates to D3R function, sex differences have not been reported. In the present study, we found significant differences between male and female monkeys at lower quinpirole doses, with females

being less sensitive to the behavioral effects of quinpirole. It is possible that the entire quinpirole dose-response curve for females is shifted to the right of males and that if higher doses of quinpirole were tested, even greater sex differences would have been observed. However, it is important to note that quinpirole-induced hypothermia was not different in drug-naïve females and males, suggesting that baseline D2R availability is not different. PET data using D2-like radiotracers in monkeys have confirmed no significant differences between male and female monkeys (Hamilton et al., 2010). Although D2-like receptor availability may not be different at baseline, our data suggest sex differences in the behavioral effects of DA agonists. Consistent with this hypothesis, an investigation of healthy human subjects reported that drug-elicited DA release in the ventral striatum, caudate nucleus, and putamen was greater in male subjects compared with females (Munro et al., 2012). Additionally, a recent study showed that female smokers have significantly higher D2-like receptor availability than male smokers (Brown et al., 2012), further supporting the growing evidence of sex differences in dopaminergic system dynamics (Becker, 1999; Dreher et al., 2007; Festa et al., 2010; Hedges et al., 2010). On the other hand, the quinpirole-elicited yawning dose-response curve has been shown to be malleable to changes in food content and body weight (Baladi and France, 2009). Although males and females in this study ate the same high-protein diet, the heaviest female weighed less than the lightest male. Whether changes in diet would similarly affect the quinpirole dose-response curve in males and females remains to be investigated.

There is evidence supporting the use of D3R antagonists and partial agonists for the treatment of cocaine and MA abuse as well as accompanying symptoms such as cognitive dysfunction (Newman et al., 2012; Mugnaini et al., 2013; Nakajima et al., 2013). Considering female rhesus monkeys in the current study were less sensitive to the behavioral effects of quinpirole, it is likely that drug potency will be a critical variable in future studies investigating D3R compounds as a treatment option. As there are known sex differences in drug pharmacokinetics and pharmacodynamics (see Gandhi et al., 2004, for review) and also that the fields of neuroscience and pharmacology publish predominately male subject-based studies (Beery and Zucker, 2011), the present findings support the consideration of sex differences as a critical variable in the development of treatment strategies for drug abuse (Zilberman et al., 2003; see Becker and Hu, 2008). Finally, this and other studies (Boileau et al., 2012; Payer et al., 2014) have associated D3R availability and a history of psychostimulant abuse but have yet to establish the nature of this relationship. Future studies will need to focus on whether high or low D3R availability is a risk factor in psychostimulant abuse or a result of exposure to the drug.

There are some limitations to the present study. The relationship between [^{11}C]PHNO binding potential and quinpirole-elicited yawning is not consistent with D3R and D2R signal in every brain region examined. For example, monkeys experienced fewer yawns with increasing D3R binding potential in the ventral pallidum. This relationship is not consistent with the high D3R signal reported in that brain region (Tziortzi et al., 2011), suggesting a possible alternative mechanism. Past studies have implicated specific brain areas in dopamine agonist-elicited yawning, including the nigrostriatal pathway, hypothalamus, and the paraventricular nucleus (Dourish and

Hutson, 1985; Melis et al., 1987); thus, it is expected that yawning does not necessarily have to correlate with D3R and D2R signal in every brain region. Furthermore, yawning is not limited to dopaminergic modulation and several other neurotransmitters and neurohormones are involved (Argiolas and Melis, 1998), creating a complex neural circuit (Sanna et al., 2012) that requires additional testing.

Acknowledgments

The authors thank H. Donald Gage for PMOD assistance.

Authorship Contributions

Participated in research design: Martelle, S. H. Nader, Czoty, John, Duke, P. K. Garg, Newman, M. A. Nader.

Conducted experiments: Martelle, S. H. Nader, John, S. Garg, Newman.

Performed data analysis: Martelle, S. H. Nader, Duke.

Wrote or contributed to the writing of the manuscript: Martelle, S. H. Nader, Czoty, John, Duke, P. K. Garg, S. Garg, Newman, M. A. Nader.

References

- Achat-Mendes C, Platt DM, Newman AH, and Spealman RD (2009) The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys. *Psychopharmacology (Berl)* **206**:73–84.
- Argiolas A and Melis MR (1998) The neuropharmacology of yawning. *Eur J Pharmacol* **343**:1–16.
- Baladi MG and France CP (2009) High fat diet and food restriction differentially modify the behavioral effects of quinpirole and raclopride in rats. *Eur J Pharmacol* **610**:55–60.
- Becker JB (1999) Gender differences in dopaminergic function in striatum and nucleus accumbens. *Pharmacol Biochem Behav* **64**:803–812.
- Becker JB and Hu M (2008) Sex differences in drug abuse. *Front Neuroendocrinol* **29**:36–47.
- Beery AK and Zucker I (2011) Sex bias in neuroscience and biomedical research. *Neurosci Biobehav Rev* **35**:565–572.
- Blaylock BL, Gould RW, Banala A, Grundt P, Luedtke RR, Newman AH, and Nader MA (2011) Influence of cocaine history on the behavioral effects of Dopamine D₃ receptor-selective compounds in monkeys. *Neuropsychopharmacology* **36**:1104–1113.
- Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, and Zack M, et al. (2012) Higher binding of the dopamine D3 receptor-preferring ligand [¹¹C](+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. *J Neurosci* **32**:1353–1359.
- Brown AK, Mandelkern MA, Farahi J, Robertson C, Ghahremani DG, Sumner B, Moallem N, and London ED (2012) Sex differences in striatal dopamine D2/D3 receptor availability in smokers and non-smokers. *Int J Neuropsychopharmacol* **15**:989–994.
- Chu PW, Seferian KS, Birdsall E, Truong JG, Riordan JA, Metcalf CS, Hanson GR, and Fleckenstein AE (2008) Differential regional effects of methamphetamine on dopamine transport. *Eur J Pharmacol* **590**:105–110.
- Code RA and Tang AH (1991) Yawning produced by dopamine agonists in rhesus monkeys. *Eur J Pharmacol* **201**:235–238.
- Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C, Chen J, Wang S, and Woods JH (2007) Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. *Psychopharmacology (Berl)* **193**:159–170.
- Collins GT, Truong YN-T, Levant B, Chen J, Wang S, and Woods JH (2011) Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. *Psychopharmacology (Berl)* **215**:609–620.
- Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, and Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. *J Pharmacol Exp Ther* **314**:310–319.
- Collins GT and Woods JH (2009) Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats. *Behav Pharmacol* **20**:492–504.
- Czoty PW, Martelle JL, and Nader MA (2006) Influence of abstinence and conditions of cocaine access on the reinforcing strength of cocaine in nonhuman primates. *Drug Alcohol Depend* **85**:213–220.
- Degenhardt L and Hall W (2012) Extent of illicit drug use and dependence, and their contribution to the global burden of disease. *Lancet* **379**:55–70.
- Dourish CT and Hutson PH (1985) Bilateral lesions of the striatum induced with 6-hydroxydopamine abolish apomorphine-induced yawning in rats. *Neuropharmacology* **24**:1051–1055.
- Dreher JC, Schmidt PJ, Kohn P, Furman D, Rubinow D, and Berman KF (2007) Menstrual cycle phase modulates reward-related neural function in women. *Proc Natl Acad Sci USA* **104**:2465–2470.
- Festa ED, Shivers KY, Jenab S, and Quiñones-Jenab V (2010) Cocaine-induced sex differences in D1 dopamine receptor mRNA levels after acute cocaine administration. *Ethn Dis* **20**:S1–24–27.
- Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding YS, and Huang Y, et al. (2012) Affinity and selectivity of [¹¹C](+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. *Synapse* **66**:489–500.
- Gallezot J-D, Kloczynski T, Weinzimmer D, Labaree D, Zheng M-Q, Lim K, Rabiner EA, Ridler K, Pittman B, and Huang Y, et al. (2014) Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [¹¹C]PHNO vs [¹¹C]raclopride PET. *Neuropsychopharmacology* **39**:866–874.
- Gandhi M, Aweka F, Greenblatt RM, and Blaschke TF (2004) Sex differences in pharmacokinetics and pharmacodynamics. *Annu Rev Pharmacol Toxicol* **44**:499–523.
- Greenfield SF, Back SE, Lawson K, and Brady KT (2010) Substance abuse in women. *Psychiatr Clin North Am* **33**:339–355.
- Groman SM, Morales AM, Lee B, London ED, and Jentsch JD (2013) Methamphetamine-induced increases in putamen gray matter associate with inhibitory control. *Psychopharmacology (Berl)* **229**:527–538.
- Hamilton LR, Czoty PW, Gage HD, and Nader MA (2010) Characterization of the dopamine receptor system in adult rhesus monkeys exposed to cocaine throughout gestation. *Psychopharmacology (Berl)* **210**:481–488.
- Hedges VL, Staffend NA, and Meisel RL (2010) Neural mechanisms of reproduction in females as a predisposing factor for drug addiction. *Front Neuroendocrinol* **31**:217–231.
- Heidbreder C (2013) Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders. *Naunyn Schmiedeberg Arch Pharmacol* **386**:167–176.
- Heidbreder CA and Newman AH (2010) Current perspectives on selective dopamine D₃ receptor antagonists as pharmacotherapeutics for addictions and related disorders. *Ann N Y Acad Sci* **1187**:4–34.
- Koffarnus MN, Collins GT, Rice KC, Chen J, Woods JH, and Winger G (2012) Self-administration of agonists selective for dopamine D2, D3, and D4 receptors by rhesus monkeys. *Behav Pharmacol* **23**:331–338.
- Koob GF and Volkow ND (2010) Neurocircuitry of addiction. *Neuropsychopharmacology* **35**:217–238.
- Kuczenski R, Segal DS, Melega WP, Lacan G, and McCunney SJ (2009) Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. *Neuropsychopharmacology* **34**:2430–2441.
- Lammertsma AA and Hume SP (1996) Simplified reference tissue model for PET receptor studies. *Neuroimage* **4**:153–158.
- Le Foll B, Francès H, Diaz J, Schwartz JC, and Sokoloff P (2002) Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. *Eur J Neurosci* **15**:2016–2026.
- Letchworth SR, Nader MA, Smith HR, Friedman DP, and Porrino LJ (2001) Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. *J Neurosci* **21**:2799–2807.
- Littell RC, Henry PR, and Ammerman CB (1998) Statistical analysis of repeated measures data using SAS procedures. *J Anim Sci* **76**:1216–1231.
- Levant B (1998) Differential distribution of D₃ dopamine receptors in the brains of several mammalian species. *Brain Res* **800**:269–274.
- Lynch WJ, Roth ME, and Carroll ME (2002) Biological basis of sex differences in drug abuse: preclinical and clinical studies. *Psychopharmacology (Berl)* **164**:121–137.
- Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, and Nader MA (2007) Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. *J Pharmacol Exp Ther* **321**:573–582.
- Melis MR, Argiolas A, and Gessa GL (1987) Apomorphine-induced penile erection and yawning: site of action in brain. *Brain Res* **415**:98–104.
- Mello NK (2010) Hormones, nicotine, and cocaine: clinical studies. *Horm Behav* **58**:57–71.
- Mello NK, Knudson IM, and Mendelson JH (2007) Sex and menstrual cycle effects on progressive ratio measures of cocaine self-administration in cynomolgus monkeys. *Neuropsychopharmacology* **32**:1956–1966.
- Morissette M, Goulet M, Grondin R, Blanchet P, Bédard PJ, Di Paolo T, and Lévesque D (1998) Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. *Eur J Neurosci* **10**:2565–2573.
- Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B, Savoia C, Beaver J, Rabiner EA, Micheli F, and Heidbreder C, et al. (2013) Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. *Neuropsychopharmacology* **38**:302–312.
- Munro CA, Winicki JM, Schretlen DJ, Gower EW, Turano KA, Muñoz B, Keay L, Bandeen-Roche K, and West SK (2012) Sex differences in cognition in healthy elderly individuals. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn* **19**:759–768.
- Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, Ehrenkauffer R, and Mach RH (2006) PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. *Nat Neurosci* **9**:1050–1056.
- Nader MA, Nader SH, Czoty PW, Riddick NV, Gage HD, Gould RW, Blaylock BL, Kaplan JR, Garg PK, and Davies HM, et al. (2012) Social dominance in female monkeys: dopamine receptor function and cocaine reinforcement. *Biol Psychiatry* **72**:414–421.
- Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, Mulsant B, Pollock B, and Graff-Guerrero A (2013) The potential role of dopamine D₃ receptor neurotransmission in cognition. *Eur Neuropsychopharmacol* **23**:799–813.
- Neisewander JL, Fuchs RA, Tran-Nguyen LT, Weber SM, Coffey GP, and Joyce JN (2004) Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. *Neuropsychopharmacology* **29**:1479–1487.
- Newman AH, Grundt P, and Nader MA (2005) Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. *J Med Chem* **48**:3663–3679.

- Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, and Skolnick P (2012) Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. *Biochem Pharmacol* **84**:882–890.
- O'Brien MS and Anthony JC (2005) Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000–2001. *Neuropsychopharmacology* **30**:1006–1018.
- Orio L, Wee S, Newman AH, Pulvirenti L, and Koob GF (2010) The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. *Addict Biol* **15**:312–323.
- Payer DE, Behzadi A, Kish SJ, Houle S, Wilson AA, Rusjan PM, Tong J, Selby P, George TP, and McCluskey T, et al. (2014) Heightened D₃ dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [¹¹C]-(+)-PHNO. *Neuropsychopharmacology* **39**:311–318.
- Sanna F, Argiolas A, and Melis MR (2012) Oxytocin-induced yawning: sites of action in the brain and interaction with mesolimbic/mesocortical and incertohypothalamic dopaminergic neurons in male rats. *Horm Behav* **62**:505–514.
- Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, and Merlo-Pich E, et al. (2010) Imaging dopamine D3 receptors in the human brain with positron emission tomography, [¹¹C]PHNO, and a selective D3 receptor antagonist. *Biol Psychiatry* **68**:392–399.
- Segal DM, Moraes CT, and Mash DC (1997) Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. *Brain Res Mol Brain Res* **45**:335–339.
- Sun J, Xu J, Cairns NJ, Perlmutter JS, and Mach RH (2012) Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. *PLoS ONE* **7**:e49483.
- Staley JK and Mash DC (1996) Adaptive increase in D₃ dopamine receptors in the brain reward circuits of human cocaine fatalities. *J Neurosci* **16**:6100–6106.
- Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, Rabiner EA, and Gunn RN (2011) Imaging dopamine receptors in humans with [¹¹C]-(+)-PHNO: dissection of D3 signal and anatomy. *Neuroimage* **54**:264–277.
- Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, Franceschi D, Gatley J, and Hitzemann R, et al. (2001) Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. *Am J Psychiatry* **158**:2015–2021.
- Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, Dewey SL, Logan J, Bendriem B, and Christman D, et al. (1990) Effects of chronic cocaine abuse on postsynaptic dopamine receptors. *Am J Psychiatry* **147**:719–724.
- Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, and Ginovart N (2005) Radiosynthesis and evaluation of [¹¹C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. *J Med Chem* **48**:4153–4160.
- Yan Y, Kong H, Wu EJ, Newman AH, and Xu M (2013) Dopamine D3 receptors regulate reconsolidation of cocaine memory. *Neuroscience* **241**:32–40.
- Zilberman ML, Tavares H, Blume SB, and el-Guebaly N (2003) Substance use disorders: sex differences and psychiatric comorbidities. *Can J Psychiatry* **48**:5–13.

Address correspondence to: Dr. Michael A. Nader, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, 546 NRC, Medical Center Boulevard, Winston-Salem, NC 27157-1083. E-mail: mnader@wakehealth.edu